Metastatic Solid Tumor Clinical Trial
Official title:
A Phase I Study to Determine the Safety and Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination With Pembrolizumab in Patients With Metastatic Solid Tumors
The purpose of the research is to determine the highest dose of an oral compound called zeaxanthin that can be safely taken each day in patients with advanced cancer, the toxicity profile of zeaxanthin, and the dose of zeaxanthin to use in future cancer clinical trials.
The primary purpose of the study is to determine the safety and optimal dosing of zeaxanthin. Effects on tumor growth will also be looked at but as a secondary endpoint. This study will use a 3+3 design which means that 3 people will receive a certain dose of zeaxanthin and if well tolerated then the next group of people will receive a higher dose. This dose escalation will continue until the highest dose allowed by the study is reached, or a dose is found that is felt not to be safe. If at a given dose one of the three people develops a severe side effect, then three more people will be treated at that dose. If no additional severe side effects develop, then the dose escalation will continue. If two people at a given dose develop severe side effects, that dose will be considered dose limiting and escalation will stop. The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
| Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT05071183 -
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05530200 -
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
|
Phase 2 | |
| Active, not recruiting |
NCT04447651 -
Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
|
||
| Recruiting |
NCT04419532 -
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04137900 -
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT04585750 -
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05028478 -
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05471271 -
IL-2 PET Imaging in Advanced Solid Tumours
|
N/A | |
| Recruiting |
NCT05867121 -
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03964727 -
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT06108050 -
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05688280 -
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
|
Phase 1/Phase 2 | |
| Completed |
NCT04914117 -
A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
|
Phase 1 | |
| Completed |
NCT00997529 -
Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors
|
N/A | |
| Recruiting |
NCT04614740 -
The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06163391 -
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06415487 -
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
|
Phase 1 |